Developer docs
API playgroundTry for free, no card

Search company profiles

Korro Bio

Full company profile

uuid00006zs

Namestring
Korro Bio
Legal namestring
Korro Bio, Inc.
Websiteurl
korrobio.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing-based genetic medicines for rare and highly prevalent diseases. Founded in 2018–2019 and headquartered in Cambridge, Massachusetts, the company became publicly traded on Nasdaq (ticker: KRRO) in November 2023 through a reverse merger with Frequency Therapeutics, supported by a concurrent $117 million private placement. The company employs between 101 and 250 people post the November 2025 restructuring, with a market capitalization in the $110–157 million range as of early 2026.

The company's core technology is the OPERA (Oligonucleotide Promoted Editing of RNA) platform, a proprietary approach that co-opts endogenous ADAR enzymes to introduce precise, single-base edits to native mRNA transcripts, producing therapeutic proteins with enhanced functionality. OPERA combines ADAR biology expertise, machine learning–driven oligonucleotide design, custom linker chemistry, and clinically validated tissue-specific delivery modalities including GalNAc conjugates for liver targeting and lipid nanoparticles. First-generation designs under the CHORD (Customized High-fidelity Oligonucleotides for RNA Deamination) trademark offer high specificity and low off-target risk. The pipeline comprises KRRO-121, a GalNAc-conjugated oligonucleotide designed to generate a stabilized de novo glutamine synthetase for hyperammonemia in urea cycle disorders and hepatic encephalopathy; KRRO-111, nominated in May 2026 as a next-generation GalNAc-conjugated candidate for alpha-1 antitrypsin deficiency with >90% SERPINA1 editing in preclinical studies; an AMPKβ1 longevity/metabolic program; and a TARDBP-targeting program for ALS.

Korro Bio is pre-commercial and does not currently generate product revenue; reported Q4 2025 revenue of $1.29 million reflects collaboration activity rather than product sales, and FY2025 net loss was $117.3 million. Revenue will ultimately depend on successful clinical development, regulatory approvals (regulatory filings for KRRO-121 targeted for H2 2026), and commercialization of RNA editing therapies through specialty pharmacy distribution channels serving rare disease populations. The company held $85.2 million in cash at year-end 2025 and raised an additional $85 million via an oversubscribed PIPE financing led by Venrock Healthcare Capital Partners in March 2026, extending cash runway into the second half of 2028.

Short descriptiontext

Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing-based genetic medicines using its proprietary OPERA platform, targeting rare and prevalent diseases including urea cycle disorders, hepatic encephalopathy, alpha-1 antitrypsin deficiency, and ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA editing therapeutics, oligonucleotide-based medicines, genetic medicine platform, liver-targeted therapies, rare disease treatments
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Editing Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue (Future)
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Korro Bio does not currently generate product revenue. The company is developing RNA editing-based genetic medicines with lead candidates KRRO-121 for hyperammonemia and KRRO-111 for AATD. Revenue will depend on successful clinical development, regulatory approvals, and commercialization of these therapeutic candidates.

benzinga.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OPERA®
Description

Oligonucleotide Promoted Editing of RNA platform technology for developing RNA editing genetic medicines

korrobio.com
+1 more record
Core offering1 text field

Korro Bio is a clinical-stage biopharmaceutical company developing a new class of RNA editing-based genetic medicines through its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The platform leverages endogenous ADAR enzymes to make precise, tissue-directed single-base edits to native mRNA, generating therapeutic proteins with enhanced functionality. Lead clinical-stage candidates include KRRO-121 for hyperammonemia (urea cycle disorders and hepatic encephalopathy) and KRRO-111 for alpha-1 antitrypsin deficiency (AATD), with additional programs targeting AMPKβ1 for liver health and TARDBP for ALS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >90% SERPINA1 transcript editing with KRRO-111 in preclinical studies
+5 more records
Product overview1 text field

Korro Bio is a biopharmaceutical company developing a new class of genetic medicines based on its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The company's pipeline includes multiple programs: KRRO-121 (a GalNAc-conjugated RNA editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy), KRRO-111 (a next-generation GalNAc-conjugated candidate for Alpha-1 Antitrypsin Deficiency), an AMPKγ1/longevity program for liver health, and a TARDBP program for ALS. The platform technology leverages CHORD (Customized High-fidelity Oligonucleotides for RNA Deamination) designs combined with validated delivery modalities including GalNAc and LNPs.

Product and service4 records
1KRRO-121
CategoryDrug Candidate
Description

KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide designed to generate a stabilized, de novo variant of glutamine synthetase (GS) protein for treating hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The synthetic rescue approach augments ammonia clearance, addressing the underlying metabolic defect in hyperammonemia-driven diseases.

2KRRO-111
CategoryDrug Candidate
Description

KRRO-111 is a GalNAc-conjugated RNA editing oligonucleotide designed to address the underlying genetic cause of Alpha-1 Antitrypsin Deficiency (AATD) by editing the SERPINA1 transcript to restore production of normal AAT protein, clearing protein aggregates from liver cells and preserving lung function.

3AMPKβ1/Longevity Program
CategoryDrug Candidate
Description

A GalNAc-conjugated program targeting AMPKβ1 pathway activation in the liver for restoring metabolic status and improving liver function, designed to avoid activating AMPK in other parts of the body.

4TARDBP Program for ALS
CategoryDrug Candidate
Description

A proprietary oligonucleotide program targeting the mRNA for TAR DNA binding protein 43 (TDP-43), which is associated with the development of amyotrophic lateral sclerosis (ALS), aiming to disrupt TDP-43 protein aggregation.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Research and license agreement for RNA editing technology. Korro Bio announced pausing the collaboration for one year in November 2025 following the failure of KRRO-110 in the Phase I/IIa REWRITE trial. The pause was part of strategic restructuring to reallocate resources and extend cash runway.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Wave Life Sciences is the most direct peer, developing ADAR-mediated RNA editing oligonucleotides (PRISM platform, WVE-006 for AATD). Both companies compete on the same ADAR editing modality for overlapping liver-targeted indications including AATD.

TypeDirect peer
Description

ProQR Therapeutics develops Axiomer RNA editing oligonucleotides leveraging ADAR biology for rare genetic diseases, with overlap in liver-targeted and CNS indications. Closely comparable platform technology and target disease areas.

TypeBroad incumbent
Description

Alnylam is the established leader in GalNAc-conjugated nucleic acid therapeutics, with Korro's board director Rachel Meyers previously serving as SVP of Research. Comparable GalNAc liver delivery technology and oligonucleotide chemistry infrastructure.

TypeBroad incumbent
Description

Arrowhead develops GalNAc-conjugated RNAi triggers targeting liver indications including AATD and other rare diseases. Closely comparable delivery modality and liver-targeted rare disease strategy.

TypeBroad incumbent
Description

Ionis is the leading antisense oligonucleotide company with established liver-targeted and CNS programs for rare diseases. Comparable oligonucleotide chemistry capabilities and regulatory pathway experience.

TypeBroad incumbent
Description

Beam develops base editing and other precision genetic medicines, including liver-targeted programs for AATD and other rare diseases. Comparable approach to single-base corrections for genetic diseases.

TypeEmerging player
Description

Intellia is a co-founder-affiliated gene editing company (Nessan Bermingham, Jean-Francois Formela) developing in vivo CRISPR/Cas9 therapies including liver-targeted programs. Adjacent genetic medicine approach for similar indications.

TypeEmerging player
Description

Verve develops in vivo base editing therapies for cardiovascular and liver diseases using GalNAc delivery. Comparable liver-targeted in vivo genetic medicine approach using validated delivery technology.

TypeEmerging player
Description

Airna is an RNA editing biotech developing ADAR-based oligonucleotide therapeutics for rare diseases. Directly comparable RNA editing modality and indication focus.

TypeEmerging player
Description

Ascidian develops RNA editing therapies for neurological and other rare diseases using a distinct RNA exon editing approach. Comparable focus on RNA-level genetic correction for severe genetic diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors27 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Korro Bio

RNA Editing Therapeuticskorrobio.com

Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing-based genetic medicines using its proprietary OPERA platform, targeting rare and prevalent diseases including urea cycle disorders, hepatic encephalopathy, alpha-1 antitrypsin deficiency, and ALS.

What Korro Bio does

Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing-based genetic medicines for rare and highly prevalent diseases. Founded in 2018–2019 and headquartered in Cambridge, Massachusetts, the company became publicly traded on Nasdaq (ticker: KRRO) in November 2023 through a reverse merger with Frequency Therapeutics, supported by a concurrent $117 million private placement. The company employs between 101 and 250 people post the November 2025 restructuring, with a market capitalization in the $110–157 million range as of early 2026.

The company's core technology is the OPERA (Oligonucleotide Promoted Editing of RNA) platform, a proprietary approach that co-opts endogenous ADAR enzymes to introduce precise, single-base edits to native mRNA transcripts, producing therapeutic proteins with enhanced functionality. OPERA combines ADAR biology expertise, machine learning–driven oligonucleotide design, custom linker chemistry, and clinically validated tissue-specific delivery modalities including GalNAc conjugates for liver targeting and lipid nanoparticles. First-generation designs under the CHORD (Customized High-fidelity Oligonucleotides for RNA Deamination) trademark offer high specificity and low off-target risk. The pipeline comprises KRRO-121, a GalNAc-conjugated oligonucleotide designed to generate a stabilized de novo glutamine synthetase for hyperammonemia in urea cycle disorders and hepatic encephalopathy; KRRO-111, nominated in May 2026 as a next-generation GalNAc-conjugated candidate for alpha-1 antitrypsin deficiency with >90% SERPINA1 editing in preclinical studies; an AMPKβ1 longevity/metabolic program; and a TARDBP-targeting program for ALS.

Korro Bio is pre-commercial and does not currently generate product revenue; reported Q4 2025 revenue of $1.29 million reflects collaboration activity rather than product sales, and FY2025 net loss was $117.3 million. Revenue will ultimately depend on successful clinical development, regulatory approvals (regulatory filings for KRRO-121 targeted for H2 2026), and commercialization of RNA editing therapies through specialty pharmacy distribution channels serving rare disease populations. The company held $85.2 million in cash at year-end 2025 and raised an additional $85 million via an oversubscribed PIPE financing led by Venrock Healthcare Capital Partners in March 2026, extending cash runway into the second half of 2028.

Korro Bio firmographics

Firmographics
Name
Korro Bio
Legal name
Korro Bio, Inc.
Website
https://korrobio.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing-based genetic medicines using its proprietary OPERA platform, targeting rare and prevalent diseases including urea cycle disorders, hepatic encephalopathy, alpha-1 antitrypsin deficiency, and ALS.
Ownership category
akta.pro rank

Korro Bio industry classification

Industry
Product category
RNA Editing Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • RNA editing therapeutics
  • Oligonucleotide-based medicines
  • Genetic medicine platform
  • Liver-targeted therapies
  • Rare disease treatments

Where Korro Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Korro Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Revenue (Future): As a clinical-stage biopharmaceutical company, Korro Bio does not currently generate product revenue. The company is developing RNA editing-based genetic medicines with lead candidates KRRO-121 for hyperammonemia and KRRO-111 for AATD. Revenue will depend on successful clinical development, regulatory approvals, and commercialization of these therapeutic candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Korro Bio product offering

Product offering

Core offering

Korro Bio is a clinical-stage biopharmaceutical company developing a new class of RNA editing-based genetic medicines through its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The platform leverages endogenous ADAR enzymes to make precise, tissue-directed single-base edits to native mRNA, generating therapeutic proteins with enhanced functionality. Lead clinical-stage candidates include KRRO-121 for hyperammonemia (urea cycle disorders and hepatic encephalopathy) and KRRO-111 for alpha-1 antitrypsin deficiency (AATD), with additional programs targeting AMPKβ1 for liver health and TARDBP for ALS.

Product overview

Korro Bio is a biopharmaceutical company developing a new class of genetic medicines based on its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The company's pipeline includes multiple programs: KRRO-121 (a GalNAc-conjugated RNA editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy), KRRO-111 (a next-generation GalNAc-conjugated candidate for Alpha-1 Antitrypsin Deficiency), an AMPKγ1/longevity program for liver health, and a TARDBP program for ALS. The platform technology leverages CHORD (Customized High-fidelity Oligonucleotides for RNA Deamination) designs combined with validated delivery modalities including GalNAc and LNPs.

Differentiator

Problem solved

Functional benefit

Brands

  • OPERA®: Oligonucleotide Promoted Editing of RNA platform technology for developing RNA editing genetic medicines
  • CHORD™

Products and services

  • KRRO-121 KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide designed to generate a stabilized, de novo variant of glutamine synthetase (GS) protein for treating hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The synthetic rescue approach augments ammonia clearance, addressing the underlying metabolic defect in hyperammonemia-driven diseases.
  • KRRO-111 KRRO-111 is a GalNAc-conjugated RNA editing oligonucleotide designed to address the underlying genetic cause of Alpha-1 Antitrypsin Deficiency (AATD) by editing the SERPINA1 transcript to restore production of normal AAT protein, clearing protein aggregates from liver cells and preserving lung function.
  • AMPKβ1/Longevity Program A GalNAc-conjugated program targeting AMPKβ1 pathway activation in the liver for restoring metabolic status and improving liver function, designed to avoid activating AMPK in other parts of the body.
  • TARDBP Program for ALS A proprietary oligonucleotide program targeting the mRNA for TAR DNA binding protein 43 (TDP-43), which is associated with the development of amyotrophic lateral sclerosis (ALS), aiming to disrupt TDP-43 protein aggregation.

Quantifiable outcome

  • >90% SERPINA1 transcript editing with KRRO-111 in preclinical studies
  • +5 more outcomes

Companies that use Korro Bio

Customer profile

Segments4 records

Ideal customer profiles4 records

Korro Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Korro Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Novo NordiskcoreStrategic or Co-development Partner · 12 November 2025Research and license agreement for RNA editing technology. Korro Bio announced pausing the collaboration for one year in November 2025 following the failure of KRRO-110 in the Phase I/IIa REWRITE trial. The pause was part of strategic restructuring to reallocate resources and extend cash runway.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Korro Bio competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Wave Life Sciences is the most direct peer, developing ADAR-mediated RNA editing oligonucleotides (PRISM platform, WVE-006 for AATD). Both companies compete on the same ADAR editing modality for overlapping liver-targeted indications including AATD.
  • ProQR Therapeutics: ProQR Therapeutics develops Axiomer RNA editing oligonucleotides leveraging ADAR biology for rare genetic diseases, with overlap in liver-targeted and CNS indications. Closely comparable platform technology and target disease areas.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the established leader in GalNAc-conjugated nucleic acid therapeutics, with Korro's board director Rachel Meyers previously serving as SVP of Research. Comparable GalNAc liver delivery technology and oligonucleotide chemistry infrastructure.
  • Arrowhead Pharmaceuticals: Arrowhead develops GalNAc-conjugated RNAi triggers targeting liver indications including AATD and other rare diseases. Closely comparable delivery modality and liver-targeted rare disease strategy.
  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide company with established liver-targeted and CNS programs for rare diseases. Comparable oligonucleotide chemistry capabilities and regulatory pathway experience.
  • Beam Therapeutics: Beam develops base editing and other precision genetic medicines, including liver-targeted programs for AATD and other rare diseases. Comparable approach to single-base corrections for genetic diseases.

Emerging players

  • Intellia Therapeutics: Intellia is a co-founder-affiliated gene editing company (Nessan Bermingham, Jean-Francois Formela) developing in vivo CRISPR/Cas9 therapies including liver-targeted programs. Adjacent genetic medicine approach for similar indications.
  • Verve Therapeutics: Verve develops in vivo base editing therapies for cardiovascular and liver diseases using GalNAc delivery. Comparable liver-targeted in vivo genetic medicine approach using validated delivery technology.
  • Airna Bio: Airna is an RNA editing biotech developing ADAR-based oligonucleotide therapeutics for rare diseases. Directly comparable RNA editing modality and indication focus.
  • Ascidian Therapeutics: Ascidian develops RNA editing therapies for neurological and other rare diseases using a distinct RNA exon editing approach. Comparable focus on RNA-level genetic correction for severe genetic diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Korro Bio social profiles

Digital presence

Korro Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Korro Bio leadership team

Management profile

Number of profiles

Profiles12 records

Korro Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Korro Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Korro Bio

What does Korro Bio do?

Korro Bio is a clinical-stage biopharmaceutical company developing a new class of RNA editing-based genetic medicines through its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The platform leverages endogenous ADAR enzymes to make precise, tissue-directed single-base edits to native mRNA, generating therapeutic proteins with enhanced functionality. Lead clinical-stage candidates include KRRO-121 for hyperammonemia (urea cycle disorders and hepatic encephalopathy) and KRRO-111 for alpha-1 antitrypsin deficiency (AATD), with additional programs targeting AMPKβ1 for liver health and TARDBP for ALS.

Is Korro Bio a public or private company?

Korro Bio is a public company. It is classified as public and is currently operating.

When was Korro Bio founded?

Korro Bio was founded in 2019. It employs 51 to 100 people.

Where is Korro Bio based?

Korro Bio is headquartered in Cambridge, United States, in the North America region.

How does Korro Bio make money?

One revenue line is on record: product Revenue (Future).

Who are Korro Bio's main competitors?

Direct peers on record are Wave Life Sciences and ProQR Therapeutics. Broad incumbents are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals and Beam Therapeutics. Emerging players are Intellia Therapeutics, Verve Therapeutics, Airna Bio and Ascidian Therapeutics.

Does Korro Bio have an API?

No public API is recorded for Korro Bio.

What industry is Korro Bio in?

Korro Bio's product category is RNA Editing Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialKorro To Present At The 2026 Jefferies Global Healthcare Conference In LondonKorro will present at the 2026 Jefferies Global Healthcare Conference in London, with a live webcast and 90-day replay. The company's OPERA platform uses RNA editing to develop genetic medicines for rare and prevalent diseases, leveraging GalNAc delivery and established regulatory pathways.MarketWatchKorro Bio Slides After Novo Nordisk Ends License Pact, CollaborationKorro Bio's stock fell 11% after Novo Nordisk terminated a research collaboration and license agreement, effective Feb. 1, 2027. The company had been eligible for up to $530 million in milestone payments under the agreement. Korro reported a third-quarter net loss of $17.5 million and expects its $124.8 million in cash to fund operations through the second half of 2028.YahooKorro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Korro Bio shares rose 29.7% to $12.05 after announcing encouraging preclinical results for KRRO-111, an RNA-editing therapy for alpha-1 antitrypsin deficiency. The company plans to submit a regulatory filing in the first half of 2027, ahead of clinical trials. The stock carries a Zacks Rank of #3 (Hold).Markets DailyCAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic DiseaseKorro and Tevard presented RNA-based therapies at CAMP4, targeting genetic diseases. Korro's KRRO-121 aims to treat urea cycle disorders, with clinical dosing completed and patient testing expected in H1 next year. Tevard's engineered tRNAs target nonsense mutations, with clinical trials planned by late 2027 or early 2028.MarketBeatCAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic DiseaseKorro and Tevard presented RNA-based therapies at CAMP4, with Korro's KRRO-121 targeting urea cycle disorders and Tevard's engineered tRNAs for nonsense mutations. Korro expects patient testing in H1 next year, while Tevard aims for clinical entry by late 2027 or early 2028.TradingViewCAMP: Korro targets UCD clinical data in H2 2027; Tevard aims for clinic entry by early 2028Korro is advancing pan-UCD candidate KRRO-121, with patient dosing targeted for H1 2027 and data for H2 2027. Tevard reported preclinical protein rescue and aims for clinical entry by late 2027 or early 2028.MarketBeatKorro Bio, Inc. (NASDAQ:KRRO) Stock Has Consensus Price Target of $16.50Analysts rate Korro Bio a Moderate Buy with a consensus price target of $16.50. The stock opened at $9.31, with a 1-year range of $5.20 to $55.89. The company reported a quarterly loss of $1.07 per share, beating the consensus estimate.American Banking and Market NewsKorro Bio, Inc. (NASDAQ:KRRO) Stock Has Consensus Target Price of $16.50 According to AnalystsAnalysts rate Korro Bio with an average target price of $16.50, with a Moderate Buy consensus. The stock opened at $9.31, and the company reported a Q2 loss of $1.07 per share, beating the consensus estimate of $1.34. Insiders sold 38,269 shares over the last 90 days.Simply Wall StWill Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?Korro Bio's cash burn was US$68m in the last year, giving a cash runway of about 20 months as of June 2026. Operating revenue fell 62% during the same period, while cash burn was trimmed 7.6%. The company's market cap is US$130m, meaning last year's burn was 53% of its market value.American Banking and Market NewsCritical Review: Akebia Therapeutics (NASDAQ:AKBA) & Korro Bio (NASDAQ:KRRO)Akebia Therapeutics and Korro Bio are compared on valuation, risk, and analyst ratings. Akebia has higher revenue ($236.20M vs $2.38M) and a lower P/E ratio, with a consensus target price of $3.90 implying 386.83% upside. Korro Bio's beta is 3.13, indicating higher volatility.